147 related articles for article (PubMed ID: 25791449)
21. Discovery and optimization of phthalazinone derivatives as a new class of potent dengue virus inhibitors.
Lu D; Liu J; Zhang Y; Liu F; Zeng L; Peng R; Yang L; Ying H; Tang W; Chen W; Zuo J; Tong X; Liu T; Hu Y
Eur J Med Chem; 2018 Feb; 145():328-337. PubMed ID: 29335200
[TBL] [Abstract][Full Text] [Related]
22. Identification of sequence motifs involved in Dengue virus-host interactions.
Asnet Mary J; Paramasivan R; Shenbagarathai R
J Biomol Struct Dyn; 2016; 34(3):676-87. PubMed ID: 25905427
[TBL] [Abstract][Full Text] [Related]
23. Antiviral activity of chondroitin sulphate E targeting dengue virus envelope protein.
Kato D; Era S; Watanabe I; Arihara M; Sugiura N; Kimata K; Suzuki Y; Morita K; Hidari KI; Suzuki T
Antiviral Res; 2010 Nov; 88(2):236-43. PubMed ID: 20851716
[TBL] [Abstract][Full Text] [Related]
24. The search for nucleoside/nucleotide analog inhibitors of dengue virus.
Chen YL; Yokokawa F; Shi PY
Antiviral Res; 2015 Oct; 122():12-9. PubMed ID: 26241002
[TBL] [Abstract][Full Text] [Related]
25. Discovery of antiviral molecules for dengue: In silico search and biological evaluation.
Cabarcas-Montalvo M; Maldonado-Rojas W; Montes-Grajales D; Bertel-Sevilla A; Wagner-Döbler I; Sztajer H; Reck M; Flechas-Alarcon M; Ocazionez R; Olivero-Verbel J
Eur J Med Chem; 2016 Mar; 110():87-97. PubMed ID: 26807547
[TBL] [Abstract][Full Text] [Related]
26. Ten years of dengue drug discovery: progress and prospects.
Lim SP; Wang QY; Noble CG; Chen YL; Dong H; Zou B; Yokokawa F; Nilar S; Smith P; Beer D; Lescar J; Shi PY
Antiviral Res; 2013 Nov; 100(2):500-19. PubMed ID: 24076358
[TBL] [Abstract][Full Text] [Related]
27. Discovery of Multitarget Antivirals Acting on Both the Dengue Virus NS5-NS3 Interaction and the Host Src/Fyn Kinases.
Vincetti P; Caporuscio F; Kaptein S; Gioiello A; Mancino V; Suzuki Y; Yamamoto N; Crespan E; Lossani A; Maga G; Rastelli G; Castagnolo D; Neyts J; Leyssen P; Costantino G; Radi M
J Med Chem; 2015 Jun; 58(12):4964-75. PubMed ID: 26039671
[TBL] [Abstract][Full Text] [Related]
28. Narasin, a novel antiviral compound that blocks dengue virus protein expression.
Low JS; Wu KX; Chen KC; Ng MM; Chu JJ
Antivir Ther; 2011; 16(8):1203-18. PubMed ID: 22155902
[TBL] [Abstract][Full Text] [Related]
29. A small-molecule dengue virus entry inhibitor.
Wang QY; Patel SJ; Vangrevelinghe E; Xu HY; Rao R; Jaber D; Schul W; Gu F; Heudi O; Ma NL; Poh MK; Phong WY; Keller TH; Jacoby E; Vasudevan SG
Antimicrob Agents Chemother; 2009 May; 53(5):1823-31. PubMed ID: 19223625
[TBL] [Abstract][Full Text] [Related]
30. Structure-based screening and validation of potential dengue virus inhibitors through classical and QM/MM affinity estimation.
Ahmed M; Kumar A; Hobman TC; Barakat K
J Mol Graph Model; 2019 Jul; 90():128-143. PubMed ID: 31082639
[TBL] [Abstract][Full Text] [Related]
31. Aminopurine and aminoquinazoline scaffolds for development of potential dengue virus inhibitors.
Venkatesham A; Saudi M; Kaptein S; Neyts J; Rozenski J; Froeyen M; Van Aerschot A
Eur J Med Chem; 2017 Jan; 126():101-109. PubMed ID: 27750144
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis, and biological evaluation of antiviral agents targeting flavivirus envelope proteins.
Li Z; Khaliq M; Zhou Z; Post CB; Kuhn RJ; Cushman M
J Med Chem; 2008 Aug; 51(15):4660-71. PubMed ID: 18610998
[TBL] [Abstract][Full Text] [Related]
33. In silico design of peptide inhibitors for Dengue virus to treat Dengue virus-associated infections.
Ajmal A; Shahab M; Waqas M; Zheng G; Zulfat M; Bin Jardan YA; Wondmie GF; Bourhia M; Ali I
Sci Rep; 2024 Jun; 14(1):13130. PubMed ID: 38849372
[TBL] [Abstract][Full Text] [Related]
34. GNF-2 Inhibits Dengue Virus by Targeting Abl Kinases and the Viral E Protein.
Clark MJ; Miduturu C; Schmidt AG; Zhu X; Pitts JD; Wang J; Potisopon S; Zhang J; Wojciechowski A; Hann Chu JJ; Gray NS; Yang PL
Cell Chem Biol; 2016 Apr; 23(4):443-52. PubMed ID: 27105280
[TBL] [Abstract][Full Text] [Related]
35. Novel dengue virus NS2B/NS3 protease inhibitors.
Wu H; Bock S; Snitko M; Berger T; Weidner T; Holloway S; Kanitz M; Diederich WE; Steuber H; Walter C; Hofmann D; Weißbrich B; Spannaus R; Acosta EG; Bartenschlager R; Engels B; Schirmeister T; Bodem J
Antimicrob Agents Chemother; 2015 Feb; 59(2):1100-9. PubMed ID: 25487800
[TBL] [Abstract][Full Text] [Related]
36. Looking for inhibitors of the dengue virus NS5 RNA-dependent RNA-polymerase using a molecular docking approach.
Galiano V; Garcia-Valtanen P; Micol V; Encinar JA
Drug Des Devel Ther; 2016; 10():3163-3181. PubMed ID: 27784988
[TBL] [Abstract][Full Text] [Related]
37. Discovery of novel dengue virus NS5 methyltransferase non-nucleoside inhibitors by fragment-based drug design.
Benmansour F; Trist I; Coutard B; Decroly E; Querat G; Brancale A; Barral K
Eur J Med Chem; 2017 Jan; 125():865-880. PubMed ID: 27750202
[TBL] [Abstract][Full Text] [Related]
38. 3-O-sulfated glucuronide derivative as a potential anti-dengue virus agent.
Hidari KI; Ikeda K; Watanabe I; Abe T; Sando A; Itoh Y; Tokiwa H; Morita K; Suzuki T
Biochem Biophys Res Commun; 2012 Aug; 424(3):573-8. PubMed ID: 22776202
[TBL] [Abstract][Full Text] [Related]
39. Novel binding between pre-membrane protein and claudin-1 is required for efficient dengue virus entry.
Gao F; Duan X; Lu X; Liu Y; Zheng L; Ding Z; Li J
Biochem Biophys Res Commun; 2010 Jan; 391(1):952-7. PubMed ID: 19962368
[TBL] [Abstract][Full Text] [Related]
40. Targeting domain-III hinging of dengue envelope (DENV-2) protein by MD simulations, docking and free energy calculations.
Dubey KD; Tiwari G; Ojha RP
J Mol Model; 2017 Apr; 23(4):102. PubMed ID: 28255859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
